1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,070 | 0,119 | 31.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Probiotix Health PLC - New Partnership Agreement in Belgium | 1 | RNS | ||
| 23.06. | Probiotix Health PLC - Result of AGM | 1 | RNS | ||
| 01.06. | Probiotix Health PLC - New Partnership Agreement in Slovakia | 1 | RNS | ||
| 29.05. | Probiotix Health PLC - Notice of AGM | 1 | RNS | ||
| 26.05. | TRADING UPDATES: Pathos deal win; ProBiotix eyes "market opportunity" | 3 | Alliance News | ||
| 26.05. | Probiotix Health PLC - New Strategic Alliance in Spain and Portugal | 1 | RNS | ||
| 30.03. | Probiotix Health PLC - Final Results and Investor Presentation | 4 | RNS | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 16.03. | Probiotix Health PLC - Notice of Results and Investor Presentation | - | RNS | ||
| 17.02. | Probiotix Health PLC - PDMR Shareholding | - | RNS | ||
| 16.02. | ProBiotix says shares hit by "mistaken assumptions" of link to SkinBio | 2 | Alliance News | ||
| 16.02. | Probiotix Health PLC - Statement re Share Price Movement | 2 | RNS | ||
| 04.02. | Probiotix Health PLC - Director/PDMR Shareholding | 2 | RNS |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MUSTGROW BIOLOGICS | 0,200 | 0,00 % | Analysten bullisch! VERVIELFACHUNG möglich! TeamViewer, Atoss Software, MustGrow! | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Bei MustGrow mit seiner senfbasierten Biologika-Plattform sieht GBC Research erhebliches Potenzial für eine Neubewertung. Die Analysten... ► Artikel lesen | |
| OPTIBIOTIX HEALTH | 0,065 | +0,78 % | OptiBiotix Health - Investor presentation and Q&A | ||
| APOGEE THERAPEUTICS | 134,07 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | 0,00 % | Monte Rosa, BioAge plunge as Novo's setback casts a shadow over pipeline | ||
| EDGEWISE THERAPEUTICS | 38,430 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | +0,08 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -0,01 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen |
PROBIOTIX HEALTH PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,069 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROBIOTIX HEALTH PLC finden Sie auf Wallstreet Online.